Search
Cassava Sciences Inc
SAVAAdd to Watchlist
2.380USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
15.21MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
+13.88%
Year to Date
+20.20%
1 Year
+18.41%
Key Figures
--Open
0.000High
0.00Volume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
32.71%Turnover Ratio
2.380Prev. Close
0.000Low
0.00Turnover
LossP/E Static
0.19P/B
0.00%Div Yield TTM
-59.99%ROA
4.98052wk High
3.12Volume Ratio
-24.34MNet Profit
6.39MShares
-2.2207EPS TTM
-0.81Beta
-85.44%ROE
1.15052wk Low
14.15%Amplitude
--Gross Margin
15.21MMarket Cap
0.69Reward/Risk
4.96%Risk Rate
TradingKey Stock Score of Cassava Sciences Inc
Currency: USD Updated: 2026-03-10Key Insights
Cassava Sciences Inc's fundamentals are relatively very healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 142 out of 388 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.00.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cassava Sciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Cassava Sciences Inc Highlights
StrengthsRisks
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Overvalued
The company’s latest PE is -1.07, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 14.09M shares, decreasing 15.71% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.38M shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
5.000
Target Price
+110.08%
Upside Space
Cassava Sciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cassava Sciences Inc Info
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Ticker SymbolSAVA
CompanyCassava Sciences Inc
CEOBarry (Richard J)
Websitehttps://www.cassavasciences.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Cassava Sciences Inc (SAVA)?
The current price of Cassava Sciences Inc (SAVA) is 2.38.
What is the symbol of Cassava Sciences Inc?
The ticker symbol of Cassava Sciences Inc is SAVA.
What is the 52-week high of Cassava Sciences Inc?
The 52-week high of Cassava Sciences Inc is 4.98.
What is the 52-week low of Cassava Sciences Inc?
The 52-week low of Cassava Sciences Inc is 1.15.
What is the market capitalization of Cassava Sciences Inc?
The market capitalization of Cassava Sciences Inc is 15.21M.
Is Cassava Sciences Inc (SAVA) currently rated as Buy, Hold, or Sell?
According to analysts, Cassava Sciences Inc (SAVA) has an overall rating of Buy, with a price target of 5.00.
What is the Earnings Per Share (EPS TTM) of Cassava Sciences Inc (SAVA)?
The Earnings Per Share (EPS TTM) of Cassava Sciences Inc (SAVA) is -1.88.